Biogen (NASDAQ:BIIB) Releases Quarterly Earnings Results, Beats Expectations By $0.63 EPS

Biogen (NASDAQ:BIIB) issued its quarterly earnings results on Wednesday. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.63, FiscalAI reports. The company had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.63 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. Biogen’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the business posted $4.81 EPS.

Here are the key takeaways from Biogen’s conference call:

• Q3 revenue grew 11% year over year to $2.8 billion, driven by the growth portfolio and the first full quarter of SYFOVRE and EMPAVELI following the Apellis acquisition. Biogen raised the low end of its 2026 non-GAAP EPS outlook to $12.20–$13.00.
• The Apellis integration is progressing faster than expected, with the transaction now roughly operating-income neutral and at least $250 million in run-rate synergies targeted by the end of 2027. Biogen also expects the deal to be accretive to non-GAAP EPS in 2027.
• Biogen reported strong momentum across key growth products, including high-dose SPINRAZA, LEQEMBI, SKYCLARYS, SYFOVRE and EMPAVELI. The company said its growth portfolio represented approximately 63% of core pharmaceutical revenue and expects to return to overall top-line growth in 2026.
• The company highlighted a series of potentially important clinical catalysts, beginning with phase III SLE data for litifilimab in December and followed by readouts in cutaneous lupus, AMR and Dravet syndrome. Biogen also reported five INDs in 2026 and plans to build an early-stage pipeline of at least 20 programs over the next several years.
• Several reported Q3 sales benefited from temporary factors, including SPINRAZA conversion doses and inventory builds for SKYCLARYS and SYFOVRE, which are expected to reverse in Q4; contract manufacturing revenue is also expected to decline. VUMERITY revenue fell 11% year over year due to tighter Part D formulary management, while the upcoming pipeline readouts remain subject to clinical and regulatory risk.

Biogen Price Performance

NASDAQ:BIIB opened at $244.05 on Thursday. The firm has a market capitalization of $36.06 billion, a price-to-earnings ratio of 43.19, a P/E/G ratio of 2.99 and a beta of 0.09. Biogen has a 52-week low of $138.00 and a 52-week high of $258.78. The stock has a fifty day moving average of $225.73 and a 200 day moving average of $200.39. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on BIIB shares. Wall Street Zen lowered Biogen from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Wolfe Research raised Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a research report on Thursday, August 13th. HSBC upped their price target on Biogen from $165.00 to $175.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. TD Cowen increased their price target on Biogen from $225.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 21st. Finally, Needham & Company LLC lifted their price objective on Biogen from $256.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $245.61.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q3 results exceeded expectations: Biogen reported adjusted EPS of $2.62 versus the roughly $2.00 consensus estimate, while revenue rose 10.6% year over year to $2.80 billion, above forecasts near $2.63 billion. BIIB’s Q3 Earnings Beat, New Drugs Aid Sales
• Positive Sentiment: Newer products are driving the turnaround: Growth-portfolio revenue jumped 49% to $1.26 billion, representing 63% of core pharmaceutical sales. Rare-disease revenue increased 27% to $676 million, helped by the first full quarter of contributions from Apellis products acquired in May. Biogen Q3 Revenue Rises 11%
• Positive Sentiment: 2026 guidance improved: Biogen raised the lower end of its full-year reported non-GAAP diluted EPS outlook to $12.20, while maintaining a range of $12.20 to $13.00. Management characterized the business as having returned to growth. Biogen Has Returned To Growth
• Positive Sentiment: Some analysts see additional upside: Baird raised its price target to $290, supporting the view that Biogen’s growth portfolio can offset erosion in its older multiple-sclerosis franchise. Baird Raises Biogen Price Target
• Neutral Sentiment: Headline profitability was weaker: Biogen posted a GAAP net loss of $20.6 million, or $0.14 per share, compared with $466.5 million of net income a year earlier. The loss primarily reflected $284 million in acquired in-process research and development, upfront and milestone expenses tied largely to the RayThera acquisition. Biogen Swings to Loss
• Negative Sentiment: Valuation and positioning could limit gains: Barclays raised its target to $230 but retained an “equal weight” rating, implying downside from the recent share level. Unusually heavy put-option activity also signals increased short-term hedging or bearish speculation. Barclays Biogen Ratings

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.